New drug XYA02 takes on tough cancers in first human trial
NCT ID NCT07670312
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an early-stage trial, so the results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XYA02 (a biologic given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Life House
Sydney, New South Wales, Australia
-
Linear Clinical Research
Perth, Western Australia, Australia
-
Monash Medical Centre
Melbourne, Victoria, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
-
Westmead Hospital
Sydney, New South Wales, Australia